Diabetes Research and Clinical Practice
Volume 90, Issue 3 , Pages 231-242 , December 2010

Clinical approach to the patient with diabetes mellitus and very high insulin requirements

  • F. Ovalle

      Affiliations

    • Corresponding Author InformationTel.: +1 205 934 4171; fax: +1 205 975 9304.

Received 24 February 2010 ,Revised 10 June 2010 ,Accepted 21 June 2010.

References 

  1. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–294
  2. Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169:1718–1720
  3. Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. The Lancet. 1936;227:127–130
  4. MacBryde CM. Insulin resistance in diabetes mellitus. Arch Intern Med. 1933;52:932–944
  5. In:  Mantzoros C,  Flier J editor. Insulin resistance: the clinical spectrum. St. Louis: Mosby; 1995;
  6. American Diabetes Association . Consensus development conference on insulin resistance. American Diabetes Association, 5–6 November 1997, Diabetes Care. 1998;21:310–314
  7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  8. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes. 1982;31:795–801
  9. Olefsky JM, Revers RR, Prince M, Henry RR, Garvey WT, Scarlett JA, et al. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Adv Exp Med Biol. 1985;189:176–205
  10. Cochran E. U-500 insulin: when more with less yields success. Diabetes Spectrum. 2009;22:116–122
  11. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240–1244
  12. Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J. 2009;85:219–222
  13. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, et al. High-dose insulin therapy: is it time for U-500 insulin?. Endocr Pract. 2009;15:71–79
  14. Vidal-Puig A, Moller D. Insulin resistance: classification, prevalence, clinical manifestations, and diagnosis. In:  Azziz R,  Nestler J,  Dewailly D editor. Androgen excess disorders in women. Philadelphia: Lippincott Raven; 1997;p. 227–236
  15. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–745
  16. Tritos NA, Mantzoros CS. Clinical review 97: syndromes of severe insulin resistance. J Clin Endocrinol Metab. 1998;83:3025–3030
  17. Mendenhall EN. Tumor of the pineal body with high insulin resistance. J Indiana State Med Assoc. 1950;43:32–36illust.
  18. Rabson SM, Mendenhall EN. Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus; report of 3 cases. Am J Clin Pathol. 1956;26:283–290
  19. Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 1954;45:505–519
  20. Moller DE, Flier JS. Insulin resistance—mechanisms, syndromes, and implications. N Engl J Med. 1991;325:938–948
  21. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81:87–100
  22. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes. 1985;34:101–107
  23. Globerman H, Karnieli E. Analysis of the insulin receptor gene tyrosine kinase domain in obese patients with hyperandrogenism, insulin resistance and acanthosis nigricans (type C insulin resistance). Int J Obes Relat Metab Disord. 1998;22:349–353
  24. Hashimoto N, Makino H. Type C insulin resistance. Nippon Rinsho. 1994;52:2637–2640
  25. Nakamura F, Taira M, Hashimoto N, Makino H, Sasaki N. Familial type C syndrome of insulin resistance and short stature with possible autosomal dominant transmission. Endocrinol Jpn. 1989;36:349–358
  26. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993;118:529–539
  27. Schneider A, Bennett R. Impaired absorption of insulin as a cause insulin resistance. Diabetes. 1975;24:443
  28. Paulsen EP, Courtney JW, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes. 1979;28:640–645
  29. Schade DS, Duckworth WC. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med. 1986;315:147–153
  30. Krentz AJ. Insulin resistance. BMJ. 1996;313:1385–1389
  31. O’Brien IA, Lewin IG, Frier BM, Rodman H, Genuth S, Corrall RJ. Factitious diabetic instability. Diabet Med. 1985;2:392–394
  32. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220–1234
  33. Hegele RA. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab. 2003;14:371–377
  34. Savage DB, Semple RK, Chatterjee VK, Wales JK, Ross RJ, O’Rahilly S. A clinical approach to severe insulin resistance. Endocr Dev. 2007;11:122–132
  35. Flier JS, Moller DE, Moses AC, O’Rahilly S, Chaiken RL, Grigorescu F, et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab. 1993;76:1533–1541
  36. Paisey RB, Carey CM, Bower L, Marshall J, Taylor P, Maffei P, et al. Hypertriglyceridaemia in Alstrom's syndrome: causes and associations in 37 cases. Clin Endocrinol (Oxf). 2004;60:228–231
  37. Fernandez-Real JM, Molina A, Broch M, Ricart W, Gutierrez C, Casamitjana R, et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes. 1999;48:1108–1112
  38. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001;29:40–47
  39. Vestergaard H, Klein HH, Hansen T, Muller J, Skovby F, Bjorbaek C, et al. Severe insulin-resistant diabetes mellitus in patients with congenital muscle fiber type disproportion myopathy. J Clin Invest. 1995;95:1925–1932
  40. Uotani S, Yamaguchi Y, Yokota A, Yamasaki H, Takino H, Chikuba N, et al. Molecular analysis of insulin receptor gene in Werner's syndrome. Diabetes Res Clin Pract. 1994;26:171–176
  41. Uriuhara A, Morita S, Kuroda S, Fumoto M, Araki S, Aoyama N, et al. Severe insulin-resistant diabetes mellitus associated with hypereosinophilic syndrome. Intern Med. 1994;33:632–636
  42. Greenfield JR, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, et al. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet Med. 2009;26:79–82
  43. Mizuhashi S, Nakamura K, Mori Y, Noda M, Nakanishi K. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer. Diabetes Care. 2006;29:1711–1712
  44. Darmon P, Castera V, Koeppel M-C, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care. 2005;28:2980–12980
  45. Chen D, Misra A, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87:4845–4856
  46. Williams G, Pickup JC, Keen H. Massive insulin resistance apparently due to rapid clearance of circulating insulin. Am J Med. 1987;82:1247–1252
  47. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract. 2006;12:251–256
  48. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh). 1969;27(Suppl. 2):1–84
  49. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87:2395
  50. Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P, et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care. 2008;31:977–979
  51. Semple RK, Halberg NH, Burling K, Soos MA, Schraw T, Luan J, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717
  52. Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, et al. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab. 2006;91:3219–3223
  53. Mao CS, Riegelhuth ME, Van Gundy D, Cortez C, Melendez S, Ipp E. An overnight insulin infusion algorithm provides morning normoglycemia and can be used to predict insulin requirements in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:2466–2470
  54. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson–Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83:209–222
  55. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson–Mendenhall syndrome. J Clin Endocrinol Metab. 2004;89:1548–1554
  56. Yauger BJ, Gorden P, Park J, Cochran E, Stratton P. Effect of depot medroxyprogesterone acetate on glucose tolerance in generalized lipodystrophy. Obstet Gynecol. 2008;112:445–447
  57. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev. 2007;23:265–268
  58. Lalej-Bennis D, Selam JL, Fluteau-Nadler S, M’Bemba J, Reach G, Sorel G, et al. Extreme insulin resistance: clinical management by external subcutaneous insulin infusion. Diabetes Metab. 1997;23:533–536
  59. Riveline JP, Vantyghem MC, Fermon C, Brunet C, Gautier JF, Renard E, et al. Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients. Diabetes Metab. 2005;31:496–498
  60. Soudan B, Girardot C, Fermon C, Verlet E, Pattou F, Vantyghem MC. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab. 2003;29:539–546
  61. Dandona P. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet. 1978;2:637
  62. Dandona P, Foster M, Healey F, Greenbury E, Beckett AG. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet. 1978;2:283–285
  63. Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE. A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab. 2007;3:835–840
  64. Eriksson JW, Bremell T, Eliasson B, Fowelin J, Fredriksson L, Yu ZW. Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Diabetes Care. 1998;21:1217–1220
  65. Coll AP, Thomas S, Mufti GJ. Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med. 2004;350:310–311
  66. Segal T, Webb E, Viner R, Pusey C, Wild G, Allgrove J. Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Pediatr Diabetes. 2008;9:250–254
  67. Ellis MF. Severe insulin resistance treated with plasmapheresis: case report and discussion. Am J Crit Care. 1994;3:460–463
  68. Chong A, Lupsa B, Cochran E, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53:27–35
  69. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54:1994–2002
  70. McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol. 2007;157(Suppl. 1):S51–S56
  71. Hussain MA, Froesch ER. Treatment of type A insulin resistance with insulin-like growth factor-I. Lancet. 1993;341:1536–1537
  72. van Alfen-van der Velden AA, Noordam C, de Galan BE, Hoorweg-Nijman JJ, Voorhoeve PG, Westerlaken C. Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatr Diabetes. 2009;
  73. Brossard JH, Havrankova J, Rioux D, Bertrand S, D’Amour P. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance. Diabet Med. 1993;10:174–176
  74. Azziz R. The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response. Fertil Steril. 1994;61:570–572
  75. Elkind-Hirsch KE, Valdes CT, Malinak LR. Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril. 1993;60:634–641
  76. Pickup JC, Bilous RW, Keen H. Aprotinin and insulin resistance. Lancet. 1980;2:93–94
  77. Via M, Scurlock C, Raikhelkar J, Di Luozzo G, Mechanick JI. Chromium infusion reverses extreme insulin resistance in a cardiothoracic ICU patient. Nutr Clin Pract. 2008;23:325–328

PII: S0168-8227(10)00327-X

doi: 10.1016/j.diabres.2010.06.025

Diabetes Research and Clinical Practice
Volume 90, Issue 3 , Pages 231-242 , December 2010

Article Tools

* Image Usage & Resolution